SA523441069B1 - EphA4 جسم مضاد لـ - Google Patents
EphA4 جسم مضاد لـInfo
- Publication number
- SA523441069B1 SA523441069B1 SA523441069A SA523441069A SA523441069B1 SA 523441069 B1 SA523441069 B1 SA 523441069B1 SA 523441069 A SA523441069 A SA 523441069A SA 523441069 A SA523441069 A SA 523441069A SA 523441069 B1 SA523441069 B1 SA 523441069B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- sequence number
- heavy chain
- light chain
- cdr2
- chain
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
يتعلق الاختراع الحالي بجسم مضاد لـEphA4 قادر على الارتباط بـEphA4 وتعزيز انشطاره، وتركيبة صيدلانية تشتمل على الجسم المضاد بوصفه مكوناً نشطاً. يشتمل الجسم المضاد لـEphA4 على سلسلة ثقيلة تشتمل على CDR1 ثقيلة السلسلة بالمتوالية رقم: 30؛ وCDR2 ثقيلة السلسلة بالمتوالية رقم: 31؛ و CDR3ثقيلة السلسلة بالمتوالية رقم: 32؛ وسلسلة خفيفة تشتمل على CDR1خفيفة السلسلة بالمتوالية رقم: 33؛ و CDR2خفيفة السلسلة بالمتوالية رقم: 34؛ و CDR3خفيفة السلسلة بالمتوالية رقم: 35؛ أو سلسلة ثقيلة تشتمل على CDR1 ثقيلة السلسلة بالمتوالية رقم: 42؛ وCDR2 ثقيلة السلسلة بالمتوالية رقم: 31؛ و CDR3ثقيلة السلسلة بالمتوالية رقم: 43؛ وسلسلة خفيفة تشتمل على CDR1خفيفة السلسلة بالمتوالية رقم: 44؛ و CDR2خفيفة السلسلة بالمتوالية رقم: 34؛ و CDR3 خفيفة السلسلة بالمتوالية رقم: 35. شكل 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020214958 | 2020-12-24 | ||
| PCT/JP2021/047534 WO2022138708A1 (ja) | 2020-12-24 | 2021-12-22 | 抗EphA4抗体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SA523441069B1 true SA523441069B1 (ar) | 2024-07-02 |
Family
ID=82157006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SA523441069A SA523441069B1 (ar) | 2020-12-24 | 2023-06-06 | EphA4 جسم مضاد لـ |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20230357386A1 (ar) |
| EP (1) | EP4269588A4 (ar) |
| JP (1) | JP7796049B2 (ar) |
| KR (1) | KR20230123923A (ar) |
| CN (1) | CN116528899A (ar) |
| AR (1) | AR124467A1 (ar) |
| AU (1) | AU2021410893A1 (ar) |
| CA (1) | CA3192342A1 (ar) |
| CL (1) | CL2023001651A1 (ar) |
| CO (1) | CO2023005482A2 (ar) |
| IL (1) | IL303223A (ar) |
| JO (1) | JOP20230081A1 (ar) |
| MX (1) | MX2023004850A (ar) |
| PE (1) | PE20241066A1 (ar) |
| SA (1) | SA523441069B1 (ar) |
| TW (1) | TW202241949A (ar) |
| WO (1) | WO2022138708A1 (ar) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118234864A (zh) * | 2021-11-11 | 2024-06-21 | 卫材R&D管理有限公司 | 抗EphA4抗体 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2031064A1 (de) | 2007-08-29 | 2009-03-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verfahren zur Steigerung von Proteintitern |
| WO2012081502A1 (ja) * | 2010-12-17 | 2012-06-21 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ゼラチナーゼによるEphA4の切断反応を指標としたスクリーニング方法 |
| GB201107996D0 (en) | 2011-05-13 | 2011-06-29 | Vib Vzw | EphA4 is a diease modifier in motor neuron disease |
| EP3177320B1 (en) | 2014-07-31 | 2021-01-06 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Human monoclonal antibodies against epha4 and their use |
| PE20181051A1 (es) * | 2015-09-08 | 2018-07-03 | Eisai Randd Man Co Ltd | Anticuerpo anti-epha4 |
-
2021
- 2021-12-22 EP EP21910848.7A patent/EP4269588A4/en active Pending
- 2021-12-22 CN CN202180081671.3A patent/CN116528899A/zh active Pending
- 2021-12-22 KR KR1020237013988A patent/KR20230123923A/ko active Pending
- 2021-12-22 CA CA3192342A patent/CA3192342A1/en active Pending
- 2021-12-22 IL IL303223A patent/IL303223A/en unknown
- 2021-12-22 PE PE2023001814A patent/PE20241066A1/es unknown
- 2021-12-22 TW TW110148257A patent/TW202241949A/zh unknown
- 2021-12-22 MX MX2023004850A patent/MX2023004850A/es unknown
- 2021-12-22 AR ARP210103617A patent/AR124467A1/es unknown
- 2021-12-22 AU AU2021410893A patent/AU2021410893A1/en active Pending
- 2021-12-22 WO PCT/JP2021/047534 patent/WO2022138708A1/ja not_active Ceased
- 2021-12-22 JP JP2022571542A patent/JP7796049B2/ja active Active
- 2021-12-22 US US18/027,413 patent/US20230357386A1/en active Pending
-
2023
- 2023-04-20 JO JOJO/P/2023/0081A patent/JOP20230081A1/ar unknown
- 2023-04-28 CO CONC2023/0005482A patent/CO2023005482A2/es unknown
- 2023-06-06 SA SA523441069A patent/SA523441069B1/ar unknown
- 2023-06-07 CL CL2023001651A patent/CL2023001651A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20241066A1 (es) | 2024-05-13 |
| IL303223A (en) | 2023-07-01 |
| EP4269588A1 (en) | 2023-11-01 |
| AU2021410893A1 (en) | 2023-06-08 |
| CL2023001651A1 (es) | 2023-12-15 |
| CA3192342A1 (en) | 2022-06-30 |
| JOP20230081A1 (ar) | 2023-04-20 |
| US20230357386A1 (en) | 2023-11-09 |
| TW202241949A (zh) | 2022-11-01 |
| AR124467A1 (es) | 2023-03-29 |
| CO2023005482A2 (es) | 2023-05-19 |
| KR20230123923A (ko) | 2023-08-24 |
| AU2021410893A9 (en) | 2024-07-25 |
| CN116528899A (zh) | 2023-08-01 |
| MX2023004850A (es) | 2023-05-10 |
| JP7796049B2 (ja) | 2026-01-08 |
| JPWO2022138708A1 (ar) | 2022-06-30 |
| WO2022138708A1 (ja) | 2022-06-30 |
| EP4269588A4 (en) | 2025-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20190970A1 (es) | Anticuerpos anti-cd40 y sus usos | |
| ES2377720T3 (es) | Anticuerpos monoclonales agon�?sticos epha2 y métodos de uso de los mismos. | |
| AR117913A2 (es) | Conjugado fármaco-anticuerpo, composición farmacéutica y sus usos | |
| AR084315A1 (es) | Anticuerpos anti-notch1 | |
| CY1125181T1 (el) | Ανοσοσυζευγματα που στοχευουν adam9 και μεθοδοι χρησης αυτων | |
| PE20200294A1 (es) | Anticuerpos que se unen especificamente a pd-1 y metodos de uso | |
| PE20110797A1 (es) | Anticuerpos anti mn | |
| CO6231009A2 (es) | Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes | |
| PE20220570A1 (es) | Anticuerpo anti-epha4 humano | |
| AU2016204274A1 (en) | Antibodies that bind to OX40 and their uses | |
| PE20121516A1 (es) | Antidotos de anticoagulantes | |
| AU2021298632A8 (en) | Anti-CD70 antibody and application thereof | |
| PE20120429A1 (es) | Proteinas de enlace de miostatina | |
| EA201491571A1 (ru) | МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С АСИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ | |
| PE20201171A1 (es) | Anticuerpos de cadena pesada que se unen a cd22 | |
| PE20121579A1 (es) | Proteinas de enlace al antigeno il-23 humanas | |
| ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
| ES2572177T3 (es) | Anticuerpos neutralizantes anti-B7RP1 humanos | |
| NZ607711A (en) | Antibodies directed to her-3 and uses thereof | |
| PE20211293A1 (es) | Anticuerpos monoclonales antagonistas contra cd40 y sus usos | |
| PE20201255A1 (es) | Anticuerpos y conjugados de anticuerpo-farmaco especificos para cd123 y usos de los mismos | |
| PE20191031A1 (es) | ANTICUERPOS ANTI-C1s Y METODOS DE USO DE LOS MISMOS | |
| PE20140806A1 (es) | Anticuerpos anti-factor d humanizados y sus usos | |
| ES2625823T3 (es) | Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo | |
| JOP20210013A1 (ar) | تركيبات جسم مضاد fcrn |